Biogen (NASDAQ:BIIB) Price Target Raised to $290.00

by · The Cerbat Gem

Biogen (NASDAQ:BIIB – Free Report) had its target price upped by Robert W. Baird from $250.00 to $290.00 in a research note released on Thursday morning, MarketBeat.com reports. Robert W. Baird currently has an outperform rating on the biotechnology company’s stock.

Several other research firms also recently weighed in on BIIB. HSBC upped their price objective on shares of Biogen from $165.00 to $175.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. Wall Street Zen lowered shares of Biogen from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Wolfe Research raised shares of Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price target on the stock in a report on Thursday, August 13th. Piper Sandler reaffirmed an “overweight” rating and set a $245.00 price target (up from $225.00) on shares of Biogen in a research note on Thursday, September 3rd. Finally, UBS Group raised their price target on Biogen from $240.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Biogen has an average rating of “Moderate Buy” and a consensus price target of $251.00.

Get Our Latest Analysis on Biogen

Biogen Stock Up 1.6%

Shares of BIIB opened at $253.62 on Thursday. The stock has a fifty day moving average of $227.08 and a 200-day moving average of $201.04. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.95. Biogen has a 52 week low of $146.52 and a 52 week high of $258.78. The stock has a market capitalization of $37.49 billion, a price-to-earnings ratio of 108.38, a PEG ratio of 2.97 and a beta of 0.09.

Biogen (NASDAQ:BIIB – Get Free Report) last announced its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, topping the consensus estimate of $1.99 by $0.63. The firm had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.63 billion. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the previous year, the business earned $4.81 EPS. As a group, sell-side analysts anticipate that Biogen will post 12.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Biogen

A number of large investors have recently made changes to their positions in the company. Bell Investment Advisors Inc purchased a new position in Biogen during the 2nd quarter worth $27,000. Align Financial LLC increased its stake in Biogen by 339.3% during the third quarter. Align Financial LLC now owns 123 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 95 shares during the period. Provenance Wealth Advisors LLC purchased a new position in shares of Biogen during the third quarter worth about $29,000. Canton Hathaway LLC purchased a new position in Biogen during the 3rd quarter worth $31,000. Finally, Ashurst Perkins Coie Trust Co boosted its stake in shares of Biogen by 92.2% in the third quarter. Ashurst Perkins Coie Trust Co now owns 173 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 83 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

  • Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
  • Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
  • Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
  • Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
  • Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
  • Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.

About Biogen

(Get Free Report)

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Recommended Stories